Kalipada Pahan to Hypolipidemic Agents
This is a "connection" page, showing publications Kalipada Pahan has written about Hypolipidemic Agents.
Connection Strength
2.981
-
Gemfibrozil, food and drug administration-approved lipid-lowering drug, increases longevity in mouse model of late infantile neuronal ceroid lipofuscinosis. J Neurochem. 2017 05; 141(3):423-435.
Score: 0.564
-
Gemfibrozil, a lipid-lowering drug, increases myelin genes in human oligodendrocytes via peroxisome proliferator-activated receptor-?. J Biol Chem. 2012 Oct 05; 287(41):34134-48.
Score: 0.409
-
Gemfibrozil, a lipid-lowering drug, upregulates IL-1 receptor antagonist in mouse cortical neurons: implications for neuronal self-defense. J Immunol. 2012 Jul 15; 189(2):1002-13.
Score: 0.405
-
Gemfibrozil, a lipid-lowering drug, induces suppressor of cytokine signaling 3 in glial cells: implications for neurodegenerative disorders. J Biol Chem. 2012 Aug 03; 287(32):27189-203.
Score: 0.404
-
Gemfibrozil, stretching arms beyond lipid lowering. Immunopharmacol Immunotoxicol. 2009; 31(3):339-51.
Score: 0.319
-
Gemfibrozil ameliorates relapsing-remitting experimental autoimmune encephalomyelitis independent of peroxisome proliferator-activated receptor-alpha. Mol Pharmacol. 2007 Oct; 72(4):934-46.
Score: 0.288
-
Lipid-lowering drugs. Cell Mol Life Sci. 2006 May; 63(10):1165-78.
Score: 0.265
-
Lipid-Lowering Drug Gemfibrozil Protects Mice from Tay-Sachs Disease via Peroxisome Proliferator-Activated Receptor a. Cells. 2023 Dec 08; 12(24).
Score: 0.224
-
Gemfibrozil and fenofibrate, Food and Drug Administration-approved lipid-lowering drugs, up-regulate tripeptidyl-peptidase 1 in brain cells via peroxisome proliferator-activated receptor a: implications for late infantile Batten disease therapy. J Biol Chem. 2012 Nov 09; 287(46):38922-35.
Score: 0.103